2025
Hippocampal and amygdala subfield volumes in obsessive–compulsive disorder by medication status
Ntwatwa Z, Lochner C, Roos A, Sevenoaks T, van Honk J, Batistuzzo M, Choi S, Hoexter M, Kim M, Kwon J, Mataix-Cols D, Menchón J, Miguel E, Nakamae T, Soriano-Mas C, Veltman D, Groenewold N, van den Heuvel O, Stein D, Ipser J. Hippocampal and amygdala subfield volumes in obsessive–compulsive disorder by medication status. Journal Of Psychiatry And Neuroscience 2025, 50: e170-e180. PMID: 40398928, PMCID: PMC12114122, DOI: 10.1503/jpn.230119.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSubfield volumesMedical statusSymptom severityNeuroimaging studies of obsessive-compulsive disorderObsessive-compulsive disorder symptom severityStudies of obsessive-compulsive disorderNeurobiology of obsessive-compulsive disorderHealthy controlsObsessive-compulsive disorder severityBrain volumetric alterationsPsychotropic medication useHippocampal dentate gyrusQuadratic effects of ageAssess between-group differencesComorbid anxietyUnmedicated peopleNeuroimaging studiesPsychotropic medicationsVolumetric findingsBetween-group differencesVolumetric alterationsHippocampal subfieldsAmygdalaBrain volumeClassification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression
Aboharb F, Davoudian P, Shao L, Liao C, Rzepka G, Wojtasiewicz C, Indajang J, Dibbs M, Rondeau J, Sherwood A, Kaye A, Kwan A. Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression. Nature Communications 2025, 16: 1590. PMID: 39939591, PMCID: PMC11822132, DOI: 10.1038/s41467-025-56850-6.Peer-Reviewed Original ResearchConceptsAcute fluoxetinePsychoactive drugsMarkers of neural plasticityImmediate early gene expressionC-fos expressionChronic fluoxetineNative brain tissueBehavioral effectsPsychedelic propertiesBrain regionsChance levelEarly gene expressionPsychoactive compoundsNeural plasticityFluoxetinePsilocybinMDMAMeasuring drug actionTested malesPsychedelicsPreclinical assaysDrug actionKetamineFemale miceDrug classification
2024
Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review
Smith S, Le G, Teopiz K, Kwan A, Rhee T, Ho R, Wu J, Cao B, Ceban F, McIntyre R. Effects of cannabidiol and Δ9-tetrahydrocannabinol on cytochrome P450 enzymes: a systematic review. Drug Metabolism Reviews 2024, 56: 164-174. PMID: 38655747, DOI: 10.1080/03602532.2024.2346767.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCannabidiolCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDronabinolDrug InteractionsHumansPsychotropic DrugsConceptsCannabinoid cannabidiolDrug-drug interactionsPsychotropic medicationsPsychotropic agentsCYP450 enzymesHigh risk of drug–drug interactionsInteraction of THCEffects of cannabidiolRisk of drug-drug interactionsInduction of CYP450 enzymesActivity of CYP450 enzymesIncreased adverse effectsPsychotropic drugsPlasma levelsClinical dataTHCClinical studiesClinicians evidenceCannabidiolHigh riskInduce cytochrome P450Clinical settingCannabisCytochrome P450 enzymesSystematic review
2023
Trends in use of antipsychotics and psychoactive drugs in older patients after major surgery
Kim D, Lee H, Pawar A, Lee S, Park C, Levin R, Metzger E, Bateman B, Ely E, Pandharipande P, Pisani M, Hohmann S, Marcantonio E, Inouye S. Trends in use of antipsychotics and psychoactive drugs in older patients after major surgery. Journal Of The American Geriatrics Society 2023, 71: 3755-3767. PMID: 37676699, PMCID: PMC10841351, DOI: 10.1111/jgs.18580.Peer-Reviewed Original ResearchConceptsUse of antipsychoticsAcademic medical centerCommunity hospitalPostoperative periodHospital typeSurgical admissionsOlder patientsMajor surgeryAtypical antipsychoticsPsychoactive drugsIntensive care unit settingRetrospective cohort studyUse of haloperidolNon-ICU settingsUse of antiepilepticsProfessional society guidelinesPostoperative deliriumPatients 65Cohort studyHospital daysHypnotic useAgonist dexmedetomidineSociety guidelinesUnit settingMedical Center
2022
Psychotropic Medication Use in United States Pediatric Emergency Department Visits
Nash K, Olfson M, Rothenberg C, Anderson B, Pincus H, Venkatesh A. Psychotropic Medication Use in United States Pediatric Emergency Department Visits. Academic Pediatrics 2022, 23: 971-979. PMID: 36494030, PMCID: PMC10241984, DOI: 10.1016/j.acap.2022.11.016.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnxiety DisordersChildCross-Sectional StudiesEmergency Service, HospitalHealth Care SurveysHumansPsychotropic DrugsUnited StatesConceptsPsychotropic medication useNon-Hispanic patientsMedication useED visitsEmergency departmentPsychotropic medicationsMedication administrationBlack non-Hispanic patientsWhite non-Hispanic patientsSurvey-weighted logistic regressionBehavioral health visitsAppropriate medication usePediatric emergency departmentProportion of visitsCross-sectional analysisBehavioral health carePsychotropic polypharmacyHealth visitsMedication typeEquitable careMedicationsLogistic regressionPrivate insuranceAnxiety disordersVisitsConcomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials
Shurtz L, Schwartz C, DiStefano C, McPartland JC, Levin AR, Dawson G, Kleinhans NM, Faja S, Webb SJ, Shic F, Naples AJ, Seow H, Bernier RA, Chawarska K, Sugar CA, Dziura J, Senturk D, Santhosh M, Jeste SS. Concomitant medication use in children with autism spectrum disorder: Data from the Autism Biomarkers Consortium for Clinical Trials. Autism 2022, 27: 952-966. PMID: 36086805, PMCID: PMC9995606, DOI: 10.1177/13623613221121425.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsAutism Spectrum DisorderAutistic DisorderChildHumansPsychotropic DrugsConceptsConcomitant psychotropic medicationsPsychotropic medicationsClinical trialsMedication useSchool-aged childrenClinical representativenessSelective serotonin reuptake inhibitorsConcomitant medication useVariety of medicationsAutism spectrum disorderSerotonin reuptake inhibitorsPsychotropic medication useNew treatment optionsGreater overall impairmentCentral nervous systemSpectrum disorderMedication classesReuptake inhibitorsAlpha agonistsTreatment optionsClinical endpointsInclusion criteriaStudy populationMedicationsNervous systemEvaluation of Antipsychotic Reduction Efforts in Patients With Dementia in Veterans Health Administration Nursing Homes
Gerlach LB, Maust DT, Kales HC, Chang M, Kim HM, Wiechers IR, Zivin K. Evaluation of Antipsychotic Reduction Efforts in Patients With Dementia in Veterans Health Administration Nursing Homes. American Journal Of Psychiatry 2022, 179: 544-552. PMID: 35615813, PMCID: PMC9349465, DOI: 10.1176/appi.ajp.21060591.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationCNS-active medicationsVHA Nursing HomesNursing homesAnxiolytic prescribingOverall prescribingVeterans Health Administration nursing homesNursing home patientsNursing home residentsInterrupted time series designAntipsychotic reductionQuarterly prevalenceMedication classesOpioid medicationsAntidepressant prescribingAntipsychotic useMedication prescribingHome patientsPsychotropic medicationsLabel useHome residentsSimilar riskMedicationsPrescribingHealth Administration
2021
Impact of an interdisciplinary intervention for distress behaviors in dementia on psychotropic drug use in Veterans Health Administration Community Living Centers STAR-VA impact on psychotropic drug utilization
McConeghy KW, Curyto K, Jedele J, Intrator O, Mohr DC, Wiechers IR, Karel MJ. Impact of an interdisciplinary intervention for distress behaviors in dementia on psychotropic drug use in Veterans Health Administration Community Living Centers STAR-VA impact on psychotropic drug utilization. Geriatric Nursing 2021, 42: 1533-1540. PMID: 34739929, DOI: 10.1016/j.gerinurse.2021.10.009.Peer-Reviewed Original ResearchConceptsPsychotropic drug useDrug useVeterans Health Administration nursing homesPsychotropic medication usePsychotropic drug utilizationDistress behaviorsSTAR-VAMedication usePsychotropic useDrug utilizationCohort analysisNursing homesInterdisciplinary interventionEligible residentsStudy designTreatment effectsDementiaImportant optionResidentsBehavioral approachCasesAverage reductionDosesMonthsTrends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study.
Holder N, Woods A, Neylan TC, Maguen S, Seal KH, Bernardy N, Wiechers I, Ryder A, Urbieta AM, Cohen BE. Trends in Medication Prescribing in Patients With PTSD From 2009 to 2018: A National Veterans Administration Study. The Journal Of Clinical Psychiatry 2021, 82 PMID: 34004087, DOI: 10.4088/jcp.20m13522.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsDrug PrescriptionsHumansLongitudinal StudiesMaleMiddle AgedPractice Patterns, Physicians'Psychotropic DrugsRetrospective StudiesSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake InhibitorsStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderPercentage of patientsVeterans Health AdministrationVHA careAdjunctive medicationsOutpatient prescription recordsSSRIs/SNRIsVeterans Administration studyClinical practice guidelinesICD-10 codesAdverse side effectsEvidence-based psychotherapiesPsychotic spectrum disordersAAP useMedication classesBenzodiazepine prescriptionsMedication prescribingPrescription recordsSymptom improvementNational cohortPractice guidelinesMedicationsSide effectsICD-9Patients
2020
Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy
Duek O, Pietrzak RH, Petrakis I, Hoff R, Harpaz-Rotem I. Early discontinuation of pharmacotherapy in U.S. veterans diagnosed with PTSD and the role of psychotherapy. Journal Of Psychiatric Research 2020, 132: 167-173. PMID: 33126010, DOI: 10.1016/j.jpsychires.2020.10.005.Peer-Reviewed Original ResearchMeSH KeywordsHumansPsychotherapyPsychotropic DrugsStress Disorders, Post-TraumaticUnited StatesUnited States Department of Veterans AffairsVeteransConceptsPosttraumatic stress disorderRisk factorsEarly discontinuationMedication discontinuationPsychotropic medicationsPoor medication adherenceSimilar risk factorsStrong risk factorDeterminants of discontinuationKey risk factorsRole of psychotherapySingle medicationMedication adherenceMedication treatmentPsychiatric comorbidityAntipsychotic medicationPatient educationDiscontinuationOlder veteransMedicationsAdjunctive psychotherapyYounger veteransEarly interventionU.S. veteransVA treatmentSpinal cord stimulation and psychotropic medication use: Missing piece to the puzzle?
Hwang BY, Negoita S, Duy PQ, Anderson WS. Spinal cord stimulation and psychotropic medication use: Missing piece to the puzzle? Journal Of Clinical Neuroscience 2020, 81: 158-160. PMID: 33222907, PMCID: PMC9586422, DOI: 10.1016/j.jocn.2020.09.038.Peer-Reviewed Original ResearchConceptsPsychotropic medicationsSpinal cord stimulator therapyLow explantation rateTimes less likelihoodClasses of medicationsChronic pain managementChronic pain patientsPsychotropic medication useSpinal cord stimulationMajority of casesMedication usePain managementPain patientsDaily dosageTreatment failureCord stimulationDevice explantationRetrospective studySCS patientsExplantation ratePsychotropic useTreatment successMedication statusMedicationsModulatory effectsCharacteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov
Wallach JD, Krystal JH, Ross JS, O’Malley S. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. JAMA Psychiatry 2020, 77: 1081-1084. PMID: 32459295, PMCID: PMC7254444, DOI: 10.1001/jamapsychiatry.2020.1167.Peer-Reviewed Original ResearchMultiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder
Muvvala SB, O'Malley SS, Rosenheck R. Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. American Journal On Addictions 2020, 30: 55-64. PMID: 32805083, DOI: 10.1111/ajad.13089.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlcohol DeterrentsAlcoholismAmbulatory CareDepressive Disorder, MajorFemaleHospitalizationHumansIll-Housed PersonsMaleMental Health ServicesMiddle AgedMorbidityNaltrexonePsychotherapyPsychotropic DrugsSchizophreniaSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsVeteransConceptsAlcohol use disorderUse of naltrexonePsychotropic prescription fillsPrescription fillsUse disordersOutpatient mental health servicesCorrelates of initiationMedical-surgical hospitalizationMultiple psychiatric morbiditiesEfficacy of naltrexonePsychotropic medication useVeterans Health AdministrationPsychiatric outpatient servicesConcurrent psychiatric disordersMajor depressive disorderMental health servicesProportion of veteransNaltrexone initiationMedication usePsychiatric morbidityDepressive disorderImportant patientPsychiatric hospitalizationMultinomial logistic regressionOutpatient servicesCharacterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries.
Rhee TG, Olfson M, Sint K, Wilkinson ST. Characterization of the Quality of Electroconvulsive Therapy Among Older Medicare Beneficiaries. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32659875, DOI: 10.4088/jcp.19m13186.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyMedicare beneficiariesECT treatmentElderly individualsMaintenance courseRecipients of ECTMore ECT sessionsReceipt of psychotherapyProportion of patientsTreatment-resistant depressionOlder Medicare beneficiariesElderly Medicare beneficiariesMajor depressive disorderSubtherapeutic courseECT sessionsElderly patientsTreatment patternsImportant therapyDepressive disorderAdequate courseClinical measuresProportion of individualsGeneral populationTotal treatmentTherapyIn an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterationsPharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitors20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings
Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. American Journal Of Psychiatry 2020, 177: 706-715. PMID: 32312111, PMCID: PMC7577523, DOI: 10.1176/appi.ajp.2020.19091000.Peer-Reviewed Original Research
2019
Pharmacogenomic Testing in Psychiatry: Ready for Primetime?
Rakesh G, Sumner CR, Alexander JL, Gross LS, Pine J, Slaby A, Garakani A, Baron D. Pharmacogenomic Testing in Psychiatry: Ready for Primetime? The Journal Of Nervous And Mental Disease 2019, 208: 127-130. PMID: 31895226, DOI: 10.1097/nmd.0000000000001107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A, Mann CL, Spriggs S, DeFrancisco DR, Carbonaro S, Parvez L, Galynker II, Perkel CA, Hurd YL. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population. The Journal Of Clinical Psychiatry 2019, 80 PMID: 31265768, PMCID: PMC8445109, DOI: 10.4088/jcp.18m12539.Peer-Reviewed Original ResearchConceptsToxicology screenRelevance of sexSynthetic cannabinoid useSC usePositive urine toxicology screenCannabinoid useUrine toxicology screenRetrospective chart reviewPositive toxicology screenEffects of cannabinoidsSC usersRates of psychosisChart reviewPharmacologic treatmentClinical symptomsInpatient populationInpatient settingPsychotic presentationsUse of substancesStudy groupHigh riskPsychiatric unitCurrent evidenceControl groupPsychosisPsychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders
Rhee TG, Rosenheck RA. Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders. Journal Of Affective Disorders 2019, 252: 450-457. PMID: 31004825, PMCID: PMC6520147, DOI: 10.1016/j.jad.2019.04.018.Peer-Reviewed Original ResearchConceptsPsychotropic polypharmacyDepressive disorderDepressed adultsPsychiatric careNational Ambulatory Medical Care SurveyPsychiatric multimorbidityAmbulatory Medical Care SurveyPrevalence of polypharmacyAdjunctive treatment strategyMore psychotropic medicationsOutpatient psychiatric careContext of multimorbidityPrescription combinationsPsychiatric polypharmacyPsychotropic classesPsychotropic medicationsCare SurveyPolypharmacyTreatment strategiesMultimorbidityAdultsCareAntipsychoticsAntidepressantsDisorders
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply